ASTAGRAF XL
Total Payments
$2.2M
Transactions
442
Doctors
14
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2,989 | 11 | 7 |
| 2020 | $335,820 | 140 | 7 |
| 2019 | $959,232 | 167 | 1 |
| 2018 | $877,118 | 121 | 4 |
| 2017 | $2,140 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 434 | 100.0% |
| Food and Beverage | $170.80 | 8 | 0.0% |
Payments by Type
Research
$2.2M
434 transactions
General
$170.80
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KIDNEY TRANSPLANTATION | Astellas Pharma Global Development | $1.2M | 4 |
| To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody DSA Formation and the Development of Immune Activation IA in de Novo Kidney Transplant Recipients | Astellas Pharma Global Development | $800,631 | 0 |
| Astagraf XL to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | Astellas Pharma Global Development | $115,667 | 3 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release Astagraf XL in HLA Sensitized Kidney Transplant Recipients | Astellas US Technologies | $69,231 | 0 |
| Real-world study of once-daily, extended-release tacrolimus versus twice-daily, immediate-release tacrolimus in kidney transplantation clinical outcomes and healthcare resource utilization | Astellas Pharma Global Development | $12,907 | 4 |
| A PROSPECTIVE, PILOT TRIAL TO EVALUATE SAFETY AND TOLERABILITY OF TACROLIMUS EXTENDED-RELEASE (ASTAGRAF XL) IN HLA SENSITIZED KIDNEY TRANSPLANT RECIPIENTS | Astellas US Technologies | $9,466 | 0 |
| Astagraf XL? to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | Astellas Pharma Global Development | $2,932 | 4 |
Top Doctors Receiving Payments for ASTAGRAF XL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $2.1M | 395 |
| , MD | Transplant Surgery | Madison, WI | $5,321 | 9 |
| , M.D | Nephrology | Detroit, MI | $5,321 | 9 |
| , MD | Nephrology | Aurora, CO | $5,321 | 9 |
| , D.O | Nephrology | Dallas, TX | $4,608 | 8 |
| , MD | Nephrology | Chicago, IL | $3,227 | 1 |
| , MD | Transplant Surgery | Chicago, IL | $3,227 | 1 |
| , MD, PHD | Transplant Surgery | Chicago, IL | $3,227 | 1 |
| , MD | Transplant Surgery | New Orleans, LA | $3,227 | 1 |
| , M.D | Surgery | New York, NY | $84.83 | 3 |
| , PA-C | Physician Assistant | Ogden, UT | $18.75 | 1 |
| , MD | Obstetrics & Gynecology | Ogden, UT | $18.75 | 1 |
| , MD | Obstetrics & Gynecology | Ogden, UT | $18.75 | 1 |
| , M.D | Specialist | West Orange, NJ | $14.86 | 1 |
| , M.D | Emergency Medicine | Los Angeles, CA | $14.86 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $2.1M
- Astellas US Technologies $78,698
- Astellas Pharma US Inc $56.25
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 14
- Transactions 442
About ASTAGRAF XL
ASTAGRAF XL is a drug associated with $2.2M in payments to 14 healthcare providers, recorded across 442 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2021. In 2021, $2,989 was paid across 11 transactions to 7 doctors.
The most common payment nature for ASTAGRAF XL is "Unspecified" ($2.2M, 100.0% of total).
ASTAGRAF XL is associated with 7 research studies, including "ASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KIDNEY TRANSPLANTATION" ($1.2M).